object
describ
role
bacteria
includ
bacteri
resist
virus
includ
recent
describ
mix
bacterialevir
infect
adult
present
primari
care
lower
respiratori
tract
infect
lrti
method
adult
lrti
enrol
communityacquir
pneumonia
cap
match
control
prospect
studi
primari
care
network
europ
follow
patient
day
detect
streptococcu
pneumonia
haemophilu
influenza
assess
suscept
atyp
bacteria
virus
result
potenti
pathogen
detect
bacteri
pathogen
viral
pathogen
bacteri
viral
pathogen
common
bacteri
pathogen
isol
pneumonia
overal
cap
patient
h
influenza
overal
cap
patient
less
pneumonia
highli
resist
penicillin
h
influenza
blactamas
posit
common
viral
pathogen
detect
human
rhinoviru
influenza
virus
human
coronaviru
influenza
viru
human
parainfluenza
virus
human
respiratori
syncyti
viru
well
human
rhinoviru
human
coronaviru
human
metapneumoviru
detect
significantli
frequent
lrti
patient
control
conclus
bacteri
pathogen
identifi
approxim
one
five
adult
patient
lrti
primari
care
viral
pathogen
half
mix
infect
one
ten
penicillinresist
pneumococci
blactamaseproduc
h
influenza
uncommon
new
find
support
restrict
approach
antibiot
prescrib
lrti
use
firstlin
narrowspectrum
agent
primari
care
ieven
clin
microbiol
infect
object
describ
role
bacteria
includ
bacteri
resist
virus
includ
recent
describ
mix
bacterialevir
infect
adult
present
primari
care
lower
respiratori
tract
infect
lrti
method
adult
lrti
enrol
communityacquir
pneumonia
cap
match
control
prospect
studi
primari
care
network
europ
follow
patient
day
detect
streptococcu
pneumonia
haemophilu
influenza
assess
suscept
atyp
bacteria
virus
result
potenti
pathogen
detect
bacteri
pathogen
viral
pathogen
bacteri
viral
pathogen
common
bacteri
pathogen
isol
pneumonia
overal
cap
patient
h
influenza
overal
cap
patient
less
pneumonia
highli
resist
penicillin
h
influenza
blactamas
posit
common
viral
pathogen
detect
human
rhinoviru
influenza
virus
human
coronaviru
influenza
viru
human
parainfluenza
virus
human
respiratori
syncyti
viru
well
human
rhinoviru
human
coronaviru
human
metapneumoviru
detect
significantli
frequent
lrti
patient
control
communityacquir
lower
respiratori
tract
infect
lrti
one
commonest
reason
consult
primari
care
account
consider
antibiot
use
healthcar
cost
neither
feasibl
costeffici
identifi
microbi
aetiolog
patient
present
lrti
primari
care
sampl
challeng
limit
access
diagnost
limit
clinic
util
receiv
result
empir
treatment
decis
made
consequ
littl
known
aetiolog
lrti
everyday
primari
care
addit
detect
pathogen
symptomat
patient
contemporan
control
distinguish
asymptomat
carriag
presenc
agent
caus
symptom
rare
carri
nevertheless
despit
limit
knowledg
proport
patient
identifi
bacteri
aetiolog
sensit
pathogen
evid
limit
clinic
benefit
antibiot
treatment
half
patient
present
primari
care
lrtiacut
cough
europ
prescrib
antibiot
contribut
select
antimicrobialresist
bacteria
improv
knowledg
like
pathogen
point
care
like
suscept
bacteri
pathogen
could
help
guid
antibiot
prescrib
decis
help
contain
unnecessari
antibiot
use
antimicrobi
resist
furthermor
inform
could
support
public
health
polici
prevent
respiratori
ill
includ
vaccin
primari
object
describ
viral
bacteri
aetiolog
adult
patient
present
primari
care
lrti
communityacquir
pneumonia
cap
secondari
object
describ
presenc
resist
bacteri
infect
mix
viralebacteri
infect
studi
part
european
union
fund
network
excel
grace
genom
combat
resist
antibiot
communityacquir
lrti
europ
network
excel
wwwgracelrtiorg
recruit
patient
octob
april
primari
care
network
track
record
conduct
research
base
european
countri
antwerp
ghent
belgium
barcelona
mataro
spain
bialystok
lodz
szczecin
poland
bratislava
slovakia
cardiff
southampton
uk
jesenic
slovenia
ope
sweden
milan
itali
nice
franc
rotenburg
germani
utrecht
netherland
inclus
criteria
patient
age
year
acut
worsen
cough
day
durat
main
symptom
clinic
present
consid
caus
lrti
gener
practition
gp
consult
first
time
ill
episod
patient
presum
cough
noninfect
origin
antibiot
consumpt
previou
month
seriou
condit
associ
immunocompromis
condit
exclud
patient
plan
includ
control
patient
match
age
maximum
year
differ
gender
consult
gp
offic
reason
acut
respiratori
ill
within
period
studi
approv
local
ethic
committe
particip
centr
compet
author
countri
written
inform
consent
obtain
patient
control
particip
inclus
symptomat
patient
assess
first
present
day
day
chest
radiograph
taken
within
week
inclus
cap
consid
present
local
radiologist
report
lobar
bronchopneumonia
diagnos
categor
pneumonia
absent
recruit
gp
receiv
standard
sampl
materi
protocol
detail
instruct
sampl
patient
within
h
first
present
inclus
serum
edta
blood
sputum
avail
two
nasopharyng
flock
swab
np
copan
taken
day
serum
sampl
two
np
repeat
control
sampl
edta
blood
two
np
baselin
sputum
obtain
control
control
follow
serum
edta
np
store
frozen
local
laboratori
regular
shipment
central
laboratori
univers
hospit
antwerp
specimen
store
c
analysi
sputum
sampl
examin
local
laboratori
use
direct
microscopi
assess
qualiti
ratio
white
blood
cell
epitheli
cell
criterion
good
qualiti
gramstain
cultur
subsequ
frozen
c
streptococcu
pneumonia
h
influenza
identifi
use
convent
biochem
test
isol
frozen
microbank
ship
batch
central
laboratori
np
cultur
pneumonia
andor
h
influenza
suscept
test
karolinska
institut
oxford
univers
respect
frozen
transport
mic
pneumonia
penicillin
g
erythromycin
clindamycin
tetracyclin
levofloxacin
determin
isol
classifi
sensit
indetermin
resist
accord
eucast
breakpoint
speci
wwweucastorgantimicrobialsusceptibilitytestingbreakpoint
haemophilu
influenza
isol
test
blactamas
product
pcr
mycoplasma
pneumonia
chlamydia
pneumonia
bordetella
pertussi
legionella
pneumophila
respiratori
virus
nucleic
acid
np
extract
nuclisen
easymag
biom
erieux
marci
l
etoil
franc
antwerp
aliquot
ship
three
collabor
laboratori
subsequ
analysi
inhous
amplif
detect
method
evalu
previous
detect
pneumoniaespecif
c
pneumonia
specif
igg
igm
antibodi
pneumonia
c
pneumonia
igg
igmelisa
kit
medac
gmbh
wedel
germani
use
accord
instruct
manufactur
igg
antibodi
b
pertussi
toxin
institut
virionserion
gmbh
germani
analys
convalesc
serum
sampl
isol
pneumonia
h
influenza
identif
l
pneumophila
respiratori
virus
use
pcr
respiratori
sampl
consid
support
aetiolog
diagnosi
infect
pneumonia
c
pneumonia
defin
posit
pcr
respiratori
sampl
presenc
igm
antibodi
acutephas
serum
andor
convalescentphas
sampl
igg
seroconvers
signific
increas
igg
acut
convalesc
sampl
patient
consid
posit
acut
b
pertussi
infect
infect
last
month
posit
pcr
respiratori
sampl
andor
presenc
antibodi
titr
pertussi
toxin
iuml
convalesc
serum
day
demonstr
previous
cutoff
high
sensit
specif
gener
estim
equat
use
assess
differ
proport
potenti
pathogen
lrti
patient
day
day
sampl
day
sampl
lrti
patient
control
caseecontrol
design
appli
assess
causal
viral
pathogen
lrti
cap
chisquar
test
use
assess
differ
proport
specif
virus
bacteria
lrti
patient
without
cap
student
ttest
use
assess
differ
age
lrti
patient
without
specif
viral
bacteri
aetiolog
ibm
spss
statist
releas
p
valu
consid
statist
signific
total
adult
lrti
patient
includ
gp
octob
april
women
tabl
mean
age
year
rang
year
diagnos
cap
among
elderli
patient
year
n
patient
cap
recruit
total
control
without
symptom
lrti
day
np
blood
sampl
avail
lrti
patient
respect
sputum
sampl
day
patient
seen
blood
sampl
np
respect
could
collect
control
match
patient
accord
criteria
n
includ
estim
causal
proport
patient
lrti
cap
identifi
bacteri
viral
mix
aetiolog
present
fig
potenti
bacteri
pathogen
found
lrti
patient
day
significantli
often
patient
cap
compar
without
fig
tabl
streptococcu
pneumonia
h
influenza
significantli
preval
patient
present
cap
patient
cap
patient
vaccin
pneumonia
preval
pneumococci
group
respect
twentyfour
reduc
suscept
penicillin
g
one
isol
highli
resist
intermedi
resist
thirtysix
isol
less
suscept
erythromycinclindamycin
reduc
suscept
tetracyclin
resist
levofloxacin
twentyon
h
influenza
isol
produc
blactamas
viral
aetiolog
identifi
lrti
patient
significantli
less
often
cap
compar
without
cap
fig
tabl
commonest
virus
cohort
patient
human
rhinoviru
hrv
influenza
viru
human
coronaviru
hcov
respiratori
viru
detect
day
patient
well
match
control
respiratori
virus
except
human
adenoviru
human
bocaviru
hbov
wu
polyomaviru
ki
polyomaviru
significantli
frequent
detect
day
np
lrti
patient
day
np
np
match
control
tabl
apart
human
adenoviru
viru
preval
differ
significantli
patient
cap
lrti
lrti
patient
cap
patient
vaccin
influenza
viru
preval
influenza
viru
group
respect
casewis
analysi
atyp
bacteri
agent
virus
detect
ill
compar
subsequ
detect
follow
present
tabl
none
patient
initi
pcr
posit
pneumonia
b
pertussi
influenza
viru
human
parainfluenza
virus
remain
posit
aetiolog
follow
patient
posit
hrv
hcov
respiratori
syncyti
viru
human
metapneumoviru
hmpv
polyomavirus
hbov
pathogen
detect
follow
among
lrti
patient
mix
bacteri
mix
viral
mix
bacterialevir
infect
detect
patient
respect
pathogen
involv
describ
detail
supplementari
materi
prospect
larg
intern
caseecontrol
studi
use
standard
sampl
comprehens
microbiolog
work
provid
accur
estim
preval
bacteri
viral
aetiolog
patient
consult
lrti
primari
care
overal
microbiolog
yield
high
mainli
due
high
preval
virus
potenti
bacteri
pathogen
isol
one
five
patient
antibioticresist
pathogen
rare
previou
studi
mainli
studi
sever
ill
patient
hospit
cap
rather
lrti
primari
care
studi
use
comprehens
diagnost
method
includ
pcr
detect
respiratori
virus
identifi
potenti
pathogen
cap
patient
howev
comparison
difficult
studi
uniqu
term
studi
design
broad
inclus
criteria
high
number
patient
sampl
baselin
follow
inclus
match
control
comprehens
convent
molecular
microbiolog
diagnost
use
preval
pneumonia
h
influenza
cap
subgroup
significantli
higher
noncap
patient
lower
comparison
previou
studi
consid
implement
pneumococc
vaccin
influenc
find
small
number
cap
patient
vaccin
howev
patient
comprehens
aetiolog
studi
adult
patient
hospit
cap
usa
pneumococc
pneumonia
highlevel
penicillin
resist
pneumococci
remain
low
european
countri
set
support
recommend
antibiot
prescrib
amoxicillin
firstlin
agent
lrti
mycoplasma
pneumonia
infect
occur
epidem
everi
year
includ
patient
studi
two
epidem
wave
possibl
explain
low
pneumonia
preval
observ
also
first
larg
european
prospect
studi
preval
pertussi
adult
consult
primari
care
physician
acut
cough
detect
least
one
respiratori
viral
pathogen
almost
patient
np
sampl
may
yield
significantli
infect
respiratori
epitheli
cell
sensit
pcrbase
diagnost
techniqu
augment
specif
virus
influenza
viru
human
parainfluenza
virus
respiratori
syncyti
viru
recogn
caus
cap
hospit
patient
elderli
influenza
vaccin
result
lower
preval
influenza
viru
elderli
data
shown
hrv
hcov
hmpv
rare
detect
cap
lrti
outpati
hrv
associ
outbreak
sever
respiratori
diseas
includ
cap
older
peopl
isol
hospit
patient
cap
preval
cap
outpati
high
novel
find
hcov
recent
identifi
small
number
adult
sever
pneumonia
routin
test
adult
outpati
cap
lrti
may
underestim
preval
hcov
test
perform
gener
preval
infect
due
hmpv
mainli
describ
longterm
care
facil
found
hmpv
preval
outpati
cap
compar
lrti
even
greater
preval
cap
patient
respiratori
syncyti
viru
similar
hmpv
infect
preval
found
hospit
adult
although
number
small
human
adenoviru
significantli
preval
cap
compar
lrti
uniqu
find
immunocompet
outpati
high
rate
viral
detect
outpati
lrti
cap
suggest
comprehens
microbiolog
assess
import
guid
manag
may
explain
limit
averag
benefit
antibiot
treatment
placebocontrol
studi
conduct
larg
subset
patient
includ
present
analysi
studi
first
compar
preval
respiratori
virus
symptomat
adult
match
control
without
respiratori
symptom
influenza
viru
human
parainfluenza
virus
respiratori
syncyti
viru
never
rare
detect
control
follow
symptomat
patient
strongli
implic
agent
caus
pathogen
similarli
significantli
lower
preval
hrv
hmpv
hcov
patient
follow
control
suggest
asymptomat
carriag
virus
uncommon
adult
indic
virus
also
regard
caus
agent
cap
hrv
rate
prolong
shed
genotyp
versu
reinfect
genotyp
grace
studi
investig
human
bocaviru
detect
cap
lrti
patient
baselin
similar
find
among
control
follow
patient
hbov
identifi
respiratori
specimen
hospit
adult
altern
viral
aetiolog
control
includ
studi
hbov
often
found
presenc
pathogen
respiratori
specimen
agre
hbov
probabl
relev
primari
role
caus
agent
lrti
primari
care
may
associ
high
hbov
viral
load
hbov
viru
detect
suggest
quantit
approach
consid
also
appli
ki
polyomaviru
wu
polyomaviru
although
yet
possibl
draw
firm
conclus
role
human
patholog
data
show
evid
caus
role
outpati
cap
lrtidassess
viral
load
could
potenti
help
clarifi
signific
sputum
obtain
patient
sputa
followup
serolog
obtain
control
patient
consequ
valid
estim
preval
bacteri
pathogen
control
alway
possibl
although
import
element
studi
descript
result
also
perform
multipl
statist
test
find
statist
signific
may
reflect
type
error
howev
much
less
like
support
prior
work
aetiolog
eg
bacteri
caus
cap
pvalu
small
eg
caseecontrol
comparison
viral
aetiolog
uniqu
comprehens
prospect
studi
use
modern
microbiolog
method
suggest
tradit
view
aetiolog
cap
outpati
lrti
revis
found
viral
cap
lrti
also
caus
hrv
hcov
hmpv
high
viral
detect
rate
also
inform
clinic
decis
make
better
diagnost
need
distinguish
viral
bacteri
cap
lrti
point
care
current
studi
provid
microbiolog
evid
antibiot
help
patient
lrti
approxim
one
five
lrti
patient
bacteri
pathogen
isol
could
conceiv
benefit
antibiot
treatment
evid
support
primari
care
clinician
restrict
approach
antibiot
prescrib
lrti
consid
antibiot
inde
indic
low
resist
level
pneumonia
h
influenza
support
prescript
narrowspectrum
antibiot
declar
conflict
interest
part
work
present
eccmid
berlin
germani
septemb
larger
grace
observ
studi
design
ccb
tv
pl
sc
hg
sampl
protocol
mi
cl
kl
hg
mi
cl
pl
tv
hg
supervis
daytoday
manag
studi
site
pcr
serolog
analys
perform
kl
av
cl
kh
kz
ec
fc
avl
data
analys
mi
kl
cl
statist
analysi
perform
scthe
manuscript
draft
mi
kl
sc
hg
ccb
review
author
